The anti-BAFF/BLyS monoclonal antibody belimumab was the first approved biological therapy for autoantibody-positive SLE patients; however, the indication was restricted to non-renal manifestations. The gene discussed is TNFSF13B; the disease is systemic lupus erythematosus.